Epilogue: New Drugs for Neglected Diseases

In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion (year 2000 U.S. dollars) per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real (inflation-adjusted) rate o...

Full description

Saved in:  
Bibliographic Details
Authors: Pogge, Thomas (Author) ; Hollis, Aidan (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: Cambridge Univ. Press 2011
In: Cambridge quarterly of healthcare ethics
Year: 2011, Volume: 20, Issue: 2, Pages: 329-334
Online Access: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1827985097
003 DE-627
005 20230426094854.0
007 cr uuu---uuuuu
008 221220s2011 xx |||||o 00| ||eng c
024 7 |a 10.1017/S0963180110000988  |2 doi 
035 |a (DE-627)1827985097 
035 |a (DE-599)KXP1827985097 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Pogge, Thomas  |e VerfasserIn  |4 aut 
245 1 0 |a Epilogue: New Drugs for Neglected Diseases 
264 1 |c 2011 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a In a widely cited 2003 article, DiMasi, Hansen, and Grabowski estimated the cost of pharmaceutical research and development to be $1.1 billion (year 2000 U.S. dollars) per new medicine coming onto the market in 2001. They also estimate that this cost is going up at a real (inflation-adjusted) rate of 7.4% annually. According to these estimates, the innovation cost per new medicine today is about $2.1 billion (year 2000 U.S. dollars) or $2.65 billion (year 2010 U.S. dollars). 
700 1 |a Hollis, Aidan  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Cambridge quarterly of healthcare ethics  |d Cambridge : Cambridge Univ. Press, 1992  |g 20(2011), 2, Seite 329-334  |h Online-Ressource  |w (DE-627)306655039  |w (DE-600)1499985-7  |w (DE-576)081985010  |x 1469-2147  |7 nnns 
773 1 8 |g volume:20  |g year:2011  |g number:2  |g pages:329-334 
856 4 0 |u https://doi.org/10.1017/S0963180110000988  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/article/epilogue-new-drugs-for-neglected-diseases/19504A82A0B95C7F822D212384B43464  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
936 u w |d 20  |j 2011  |e 2  |h 329-334 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4235390007 
LOK |0 003 DE-627 
LOK |0 004 1827985097 
LOK |0 005 20221220052659 
LOK |0 008 221220||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-12-06#BACF3C4F0F50622F6B6623730244B4FCFD90B5FB 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
ORI |a SA-MARC-ixtheoa001.raw